Sarepta's ELEVIDYS Launches in Japan, Triggers $40M Milestone
Event summary
- Sarepta's ELEVIDYS (delandistrogene moxeparvovec) launched commercially in Japan via Chugai Pharmaceutical, following NHI reimbursement listing.
- First gene therapy for Duchenne muscular dystrophy (DMD) approved in Japan, targeting ambulatory patients aged 3-to-less-than-8 with specific DMD gene mutations.
- Launch triggers a $40 million milestone payment to Sarepta under its 2019 collaboration agreement with Roche.
- Chugai responsible for postmarketing studies and surveillance in Japan as part of Roche Group collaboration.
- ELEVIDYS has been administered to over 1,200 patients globally in clinical and real-world settings.
The big picture
Sarepta’s ELEVIDYS launch in Japan marks a strategic milestone in the global rollout of gene therapies for rare diseases. The partnership with Roche and Chugai underscores the growing collaboration between Western biotechs and Asian pharmaceutical firms to address unmet medical needs. With over 1,200 patients treated globally, the therapy’s sustained efficacy and safety data will be critical in securing further regulatory approvals and commercial success.
What we're watching
- Regulatory Dynamics
- Whether Japan’s conditional approval will pave the way for broader Asia-Pacific expansion.
- Commercial Execution
- How Chugai’s postmarketing studies will impact long-term efficacy and safety data.
- Revenue Impact
- The pace at which ELEVIDYS adoption in Japan will contribute to Sarepta’s top line.
Related topics